6541.TW

Tanvex BioPharma, Inc. [6541.TW] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

6541.TW Stock Summary

Top 10 Correlated Stocks

6541.TW

In the News

6541.TW Financial details

Company Rating
-
Market Cap
7.62B
Income
-2.15B
Revenue
61.41M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
197
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-3.89
Forward P/E
-
PEG
-1.7
P/S
137.36
P/B
6.03
P/C
-
P/FCF
-5.91
Quick Ratio
2.31
Current Ratio
2.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-16.65
EPS next Y
-
EPS next Q
-
EPS this Y
21.18%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
78%
EPS Q/Q
2.41%
-
-
-
-
SMA20
-4.36%
SMA50
1.74%
SMA100
8.9%
Inst Own
-
Inst Trans
-
ROA
-62%
ROE
-153%
ROC
-0.67%
Gross Margin
88%
Oper. Margin
-3390%
Profit Margin
-3527%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
48.05-89.8
52W High
-37.64%
52W Low
+15.63%
RSI
47.17
Rel Volume
1.04
Avg Volume
310.75K
Volume
323.62K
Perf Week
0%
Perf Month
7.14%
Perf Quarter
-0.89%
Perf Half Y
-2.46%
-
-
-
-
Beta
0.303
-
-
Volatility
0.93%, 3.61%
Prev Close
0.36%
Price
55.5
Change
1.46%

Something similar

Top by Market Cap
BRYN.DE
META
AMZN
BRH.DE
MSFT
Same Sector
DICE
0LSZ.L
AGTC
600161.SS
ASCN.SW
Top Correlated Stocks
1517.TW
6582.TW
1327.HK
0519.HK
JINDALPHOT.NS
Similar Market Cap
9074.T
002584.SZ
OMRNY
CEN.NZ
1333.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 310.75K
  • Market Capitalization 7.62B
  • Employee 197
  • CEO Dr. Lin-Cheng Chen J.D.
  • Headquarters George Town,KY
  • IPO Date 2015-08-13
  • Website https://www.tanvex.com

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.